Xeris Pharmaceuticals (XERS)
(Real Time Quote from BATS)
$1.73 USD
-0.02 (-1.14%)
Updated Apr 29, 2024 11:26 AM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Income Statements
Fiscal Year end for Xeris Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 164 | 110 | 50 | 20 | 3 |
Cost Of Goods | 29 | 23 | 13 | 9 | 2 |
Gross Profit | 135 | 88 | 36 | 11 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 179 | 170 | 151 | 95 | 124 |
Income After Depreciation & Amortization | -44 | -82 | -115 | -84 | -122 |
Non-Operating Income | 7 | 1 | 0 | 3 | 4 |
Interest Expense | 27 | 15 | 7 | 11 | 7 |
Pretax Income | -64 | -96 | -123 | -91 | -126 |
Income Taxes | -1 | -1 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -62 | -95 | -123 | -91 | -126 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | -95 | -123 | -91 | -126 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -68 | -112 | -81 | -120 |
Depreciation & Amortization (Cash Flow) | 15 | 14 | 3 | 2 | 2 |
Income After Depreciation & Amortization | -44 | -82 | -115 | -84 | -122 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 137.68 | 135.63 | 79.03 | 42.64 | 26.11 |
Diluted EPS Before Non-Recurring Items | -0.45 | -0.68 | -1.54 | -2.14 | -4.81 |
Diluted Net EPS (GAAP) | -0.45 | -0.70 | -1.55 | -2.14 | -4.81 |
Fiscal Year end for Xeris Biopharma Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 44.39 | 48.32 | 38.01 | 33.20 |
Cost Of Goods | NA | 7.57 | 8.20 | 7.56 | 5.32 |
Gross Profit | NA | 36.82 | 40.12 | 30.45 | 27.88 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 46.66 | 45.03 | 46.44 | 41.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.84 | -4.91 | -15.99 | -13.28 |
Non-Operating Income | NA | 3.23 | -0.77 | 1.99 | 2.66 |
Interest Expense | NA | 7.02 | 6.85 | 6.53 | 6.22 |
Pretax Income | NA | -13.63 | -12.53 | -20.52 | -16.83 |
Income Taxes | NA | -0.24 | -0.34 | -0.68 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.39 | -12.19 | -19.84 | -16.83 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.39 | -12.19 | -19.84 | -16.83 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 138.13 | 138.06 | 137.34 | 137.14 |
Diluted EPS Before Non-Recurring Items | NA | -0.10 | -0.09 | -0.14 | -0.12 |
Diluted Net EPS (GAAP) | NA | -0.10 | -0.09 | -0.14 | -0.12 |